Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis

Ho, G. T.; Lee, H. M.; Brydon, G.; Ting, T.; Hare, N.; Drummond, H.; Shand, A. G.; Bartolo, D. C.; Wilson, R. G.; Dunlop, M. G.; Arnott, I. D.; Satsangi, J.
March 2009
American Journal of Gastroenterology;Mar2009, Vol. 104 Issue 3, p673
Academic Journal
OBJECTIVES:Calprotectin is a granulocyte neutrophil-predominant cytosolic protein. Fecal concentrations are elevated in intestinal inflammation and may predict relapse in quiescent inflammatory bowel disease. We aim to investigate fecal calprotectin (FC) as a biomarker in predicting the clinical course of acute severe ulcerative colitis (ASUC).METHODS:In 90 patients with ASUC requiring intensive in-patient medical therapy (January 2005–September 2007), we investigated the discriminant ability of FC to predict colectomy and corticosteroid and infliximab nonresponse. All patients received parenteral corticosteroids as first-line treatment; 21 (23.3%) were also treated with infliximab (5 mg/kg), after failure of corticosteroid therapy.RESULTS:Of 90 patients, 31 (34.4%) required colectomy, including 11 (52.4%) of those treated with infliximab. Overall FC was high (1,020.0 μg/g interquartile range: 601.5–1,617.5). FC was significantly higher in patients requiring colectomy (1,200.0 vs. 887.0; P=0.04), with a trend toward significance when comparing corticosteroid nonresponders and responders (1,100.0 vs. 863.5; P=0.08), as well as between infliximab nonresponders and responders (1,795.0 vs. 920.5; P=0.06). Receiver–operator characteristic curve analysis yielded an area under the curve of 0.65 to predict colectomy (P=0.04), with a maximum likelihood ratio of 9.23, specificity 97.4%, and sensitivity 24.0% at a cutoff point of 1,922.5 μg/g. Kaplan–Meier analyses showed that using 1,922.5 μg/g over a median follow-up of 1.10 years, 87% of patients will need subsequent colectomy.CONCLUSIONS:This is the first data set to demonstrate that FC levels are dramatically elevated in severe UC. These data raise the possibility that this biomarker can predict response to first or second-line medical therapy in this setting.Am J Gastroenterol 2009; 104: 673–678; doi:10.1038/ajg.2008.119; published online 17 February 2009


Related Articles

  • ANORECTAL COMPLICATIONS OF CHRONIC ULCERATIVE COLITIS AND REGIONAL ENTERITIS. Granet, Emil // American Journal of Gastroenterology;May1956, Vol. 25 Issue 5, p472 

    Examines the anorectal complications of chronic ulcerative colitis and regional enteritis. Frequency of the occurrence of anorectal complications in longstanding and severe ulcerative colitis and regional enteritis; Limitation of anorectal complications in regional enteritis to suppurative and...

  • British gastroenterologists' care profile for patients with inflammatory bowel disease: the need for a patients' charter. Probert, C.S.J.; Jayanthi, V.; Mayberry, J. F. // Journal of the Royal Society of Medicine;May1993, Vol. 86 Issue 5, p271 

    The follow-up of patients with inflammatory bowel disease (IBD) was investigated using a postal questionnaire sent to 359 members of the British Society of Gastroenterology (BSG), of whom 235 replied. Of patients with IBD, 96% were weighed on each outpatient clinic review and over 60% had their...

  • Can We Immunogenotypically and Immunophenotypically Profile Patients Who are at Risk for Pouchitis? Shen, Bo; Lashner, Bret // American Journal of Gastroenterology;Mar2004, Vol. 99 Issue 3, p442 

    Comments on the immunogenotyping and immunophenotyping of patients who are at risk for pouchitis. Goals of immunogenotyping and immunophenotyping; Factors contributing to the inconsistency and discrepancy to the difficulty in conducting and interpreting clinical studies on pouchitis;...

  • Manipulation of Intestinal Microbial Flora for Therapeutic Benefit in Inflammatory Bowel Diseases: Review of Clinical Trials of Probiotics, Prebiotics and Synbiotics. Heilpern, Debra; Szilagyi, Andrew // Reviews on Recent Clinical Trials;Sep2008, Vol. 3 Issue 3, p167 

    Pathogenesis of Inflammatory Bowel Diseases(Ulcerative Colitis, Crohn's disease and Pouchitis) includes an abnormal immunological response to disturbed intestinal microflora. Therapeutic strategies are designed to intervene in these abnormal host microbial communications. A novel approach in the...

  • Characterization of the Gut-Associated Microbiome in Inflammatory Pouch Complications Following Ileal Pouch-Anal Anastomosis. Tyler, Andrea D.; Knox, Natalie; Kabakchiev, Boyko; Milgrom, Raquel; Kirsch, Richard; Cohen, Zane; McLeod, Robin S.; Guttman, David S.; Krause, Denis O.; Silverberg, Mark S. // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Introduction:Inflammatory complications following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC) are common and thought to arise through mechanisms similar to denovo onset inflammatory bowel disease. The aim of this study was to determine whether specific organisms in the...

  • Appendectomy and Protection against Ulcerative Colitis. Andersson, Roland E.; Olaison, Gunnar; Tysk, Curt; Ekbom, Anders // New England Journal of Medicine;03/15/2001, Vol. 344 Issue 11, p808 

    Background: A history of appendectomy is rare in patients with ulcerative colitis. This suggests a protective effect of appendectomy or that appendicitis and ulcerative colitis are alternative inflammatory responses. We sought to characterize this inverse relation further. Methods: We studied a...

  • Contribution of IBD5 Locus to Clinical Features of IBD Patients. Latiano, Anna; Palmieri, O.; Valvano, Rossella M.; D’Incà, Renata; Vecchi, Maurizio; Ferraris, Angelo; Sturniolo, Giacomo C.; Spina, Luisa; Lombardi, Giovanni; Dallapiccola, Bruno; Andriulli, Angelo; Devoto, Marcella; Annese, Vito // American Journal of Gastroenterology;Feb2006, Vol. 101 Issue 2, p318 

    AIM: The aim of this study was to investigate the influence of the IBD5 locus on clinical features of inflammatory bowel disease (IBD) patients, and its possible interaction with the CARD15 gene. PATIENTS AND METHODS: A cohort of 1,199 IBD patients (570 with CD and 629 with ulcerative colitis...

  • Peripheral Arthritis in the Course of Inflammatory Bowel Diseases. Yüksel, İlhami; Ataseven, Hilmi; Başar, Ömer; Köklü, Seyfettin; Ertuğrul, İbrahim; Ülker, Aysel; Dağlı, Ülkü; Şaşmaz, Nurgül // Digestive Diseases & Sciences;Jan2011, Vol. 56 Issue 1, p183 

    Background: Musculoskeletal disorders are well-defined extra-intestinal manifestations of inflammatory bowel diseases (IBD). There is little data regarding the frequencies of IBD and extra-intestinal manifestations from Central and East Europe and Middle Eastern countries. Aims: To determine the...

  • Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). Matthes, Harald; Krummenerl, Thomas; Giensch, Manfred; Wolff, Corinna; Schulze, Jürgen // BMC Complementary & Alternative Medicine;2010, Vol. 10, p13 

    Background: Probiotics are effective in inflammatory bowel diseases. Clinical effectiveness and dose dependency of E. coli Nissle (EcN) enemas were investigated in ulcerative colitis (UC). Methods: In a double-blind study, 90 patients with moderate distal activity in UC were randomly assigned to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics